Voyager Therapeutics, Inc. (VYGR) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
VYGR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VYGR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -326.6% | -296.5% |
| 2024 | 100.0% | -104.1% | -81.3% |
| 2023 | 63.1% | 48.8% | 52.9% |
| 2022 | -36.3% | -124.3% | -113.4% |
| 2021 | -97.2% | -196.8% | -190.3% |
Download Data
Export VYGR earnings history in CSV or JSON format
Free sign-in required to download data
Voyager Therapeutics, Inc. (VYGR) Earnings Overview
As of May 8, 2026, Voyager Therapeutics, Inc. (VYGR) reported trailing twelve-month net income of -$120M, reflecting -80.5% year-over-year growth. The company earned $-2.04 per diluted share over the past four quarters, with a net profit margin of -296.5%.
Looking at the long-term picture, VYGR's historical earnings data spans multiple years. The company achieved its highest annual net income of $132M in fiscal 2023.
Voyager Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), VYGR has room to improve margins relative to the peer group. Compare VYGR vs SRPT →
VYGR Earnings vs Peers
Earnings metrics vs comparable public companies
VYGR Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$120M | -84.2% | -$132M | $-2.04 | -296.5% | -326.6% |
| 2024 | -$65M | -149.1% | -$83M | $-1.13 | -81.3% | -104.1% |
| 2023 | $132M | +385.1% | $122M | $2.97 | 52.9% | 48.8% |
| 2022 | -$46M | +34.8% | -$51M | $-1.21 | -113.4% | -124.3% |
| 2021 | -$71M | -293.8% | -$74M | $-1.75 | -190.3% | -196.8% |
| 2020 | $37M | +184.3% | $27M | $0.98 | 21.5% | 16.0% |
| 2019 | -$44M | +50.6% | -$52M | $-1.14 | -41.8% | -49.5% |
| 2018 | -$88M | -24.9% | -$91M | $-2.75 | -1158.8% | -1195.6% |
| 2017 | -$71M | -75.9% | -$72M | $-2.64 | -697.6% | -709.1% |
| 2016 | -$40M | -35.5% | -$41M | $-1.59 | -282.7% | -290.4% |
See VYGR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYGR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYGR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVYGR — Frequently Asked Questions
Quick answers to the most common questions about buying VYGR stock.
Is VYGR growing earnings?
VYGR EPS fell to $-2.04, with earnings declining -80.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-120M.
What are VYGR's profit margins?
Voyager Therapeutics, Inc. net margin is -296.5%, with operating margin at -326.6%. Below-average margins reflect competitive or cost pressures.
How consistent are VYGR's earnings?
VYGR earnings data spans 2013-2025. The declining earnings trend is -80.5% YoY. Historical data enables comparison across business cycles.